EP2403833A4 - 8-substituted quinolines and related analogs as sirtuin modulators - Google Patents

8-substituted quinolines and related analogs as sirtuin modulators

Info

Publication number
EP2403833A4
EP2403833A4 EP10749227A EP10749227A EP2403833A4 EP 2403833 A4 EP2403833 A4 EP 2403833A4 EP 10749227 A EP10749227 A EP 10749227A EP 10749227 A EP10749227 A EP 10749227A EP 2403833 A4 EP2403833 A4 EP 2403833A4
Authority
EP
European Patent Office
Prior art keywords
related analogs
substituted quinolines
sirtuin modulators
sirtuin
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10749227A
Other languages
German (de)
French (fr)
Other versions
EP2403833A1 (en
Inventor
Chi B Vu
Rebecca L Casaubon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of EP2403833A1 publication Critical patent/EP2403833A1/en
Publication of EP2403833A4 publication Critical patent/EP2403833A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP10749227A 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators Withdrawn EP2403833A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15674909P 2009-03-02 2009-03-02
PCT/US2010/025963 WO2010101949A1 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators

Publications (2)

Publication Number Publication Date
EP2403833A1 EP2403833A1 (en) 2012-01-11
EP2403833A4 true EP2403833A4 (en) 2012-08-29

Family

ID=42709991

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10749227A Withdrawn EP2403833A4 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators

Country Status (11)

Country Link
EP (1) EP2403833A4 (en)
JP (1) JP2012519211A (en)
KR (1) KR20110128908A (en)
CN (1) CN102414180A (en)
AU (1) AU2010221417A1 (en)
BR (1) BRPI1011477A2 (en)
CA (1) CA2754058A1 (en)
EA (1) EA201171098A1 (en)
IL (1) IL214943A0 (en)
MX (1) MX2011009213A (en)
WO (1) WO2010101949A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190603A1 (en) 2008-05-01 2013-06-28 Sirtris Pharmaceuticals Inc Quinolines and related analogs as sirtuin modulators
KR20110036602A (en) 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 Benzimidazole and related analogs as sirtuin modulators
US8987258B2 (en) 2008-09-29 2015-03-24 Christopher Oalmann Chromenone analogs as sirtuin modulators
IN2012DN03799A (en) 2009-10-29 2015-08-28 Sirtris Pharmaceuticals Inc
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP5951650B2 (en) 2011-03-18 2016-07-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ N- (3-carbamoylphenyl) -1H-pyrazole-5-carboxamide derivatives and their use for controlling pests
CN102250151B (en) * 2011-05-17 2013-11-06 中国科学院化学研究所 2-arimid-8-benzimidazol quinoline transition metal compound and preparation method and use thereof
JP6029668B2 (en) 2011-08-29 2016-11-24 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
WO2013059589A1 (en) * 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
KR20140077963A (en) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
JP2015512891A (en) 2012-03-13 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Bactericidal pyrimidine compounds
CN104812387A (en) 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 Substituted 1,6-naphthyridines
RS58768B1 (en) 2013-03-14 2019-06-28 Merck Patent Gmbh Glycosidase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP3004094B1 (en) 2013-06-04 2017-03-01 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
TWI529171B (en) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-naphthyridine derivatives
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CN105722833A (en) 2013-09-16 2016-06-29 巴斯夫欧洲公司 Fungicidal pyrimidine compounds
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
JP6112724B2 (en) * 2013-10-31 2017-04-12 日本化薬株式会社 1,5-naphthyridine derivative and insecticide comprising the same as an active ingredient
EP3068781B1 (en) 2013-11-12 2017-12-20 F. Hoffmann-La Roche AG Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
TW201612161A (en) 2014-01-20 2016-04-01 Bayer Cropscience Ag Quinoline derivatives as insecticides and acaricides
EP3107920B1 (en) 2014-02-19 2017-10-18 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
CN106414448B (en) 2014-05-23 2019-04-19 活跃生物技术有限公司 Novel compounds useful as S100-inhibitors
EP3169678A1 (en) * 2014-07-17 2017-05-24 Merck Patent GmbH Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
EP3174868B1 (en) 2014-08-01 2021-08-25 Nuevolution A/S Compounds active towards bromodomains
MA53944A (en) 2014-08-28 2021-08-25 Asceneuron Sa GLYCOSIDASE INHIBITORS
CN107001361A (en) 2014-12-02 2017-08-01 拜耳医药股份有限公司 Imidazo [1,2 a] pyridine of heteroaryl substitution and application thereof
CN104592109A (en) * 2015-01-19 2015-05-06 湖南华腾制药有限公司 Method for preparing 8-bromoquinoline derivative
EP3256217A1 (en) * 2015-02-11 2017-12-20 Basilea Pharmaceutica International AG Substituted mono- and polyazanaphthalene derivatives and their use
CN108884078A (en) 2016-02-25 2018-11-23 阿森纽荣股份公司 Glycosidase inhibitor
JP2019510006A (en) 2016-02-25 2019-04-11 エースニューロン・ソシエテ・アノニム Glycosidase inhibitor
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
AU2017222962B2 (en) 2016-02-25 2021-03-25 Asceneuron S. A. Acid addition salts of piperazine derivatives
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
ES2954474T3 (en) 2018-08-22 2023-11-22 Asceneuron Sa Succinate and fumarate acid addition salts of piperazine derivatives useful as glucosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
CN113993587A (en) * 2019-02-28 2022-01-28 科智生命科学公司 Thiazole derivatives as protein secretion inhibitors
CN110964011B (en) * 2019-12-16 2022-06-21 诚达药业股份有限公司 Synthetic method of 8-chloro-1, 7-naphthyridine-3-formaldehyde
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202337453A (en) 2022-03-17 2023-10-01 美商英塞特公司 Tricyclic urea compounds as jak2 v617f inhibitors
WO2024059212A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024059216A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
TW202506671A (en) * 2023-04-23 2025-02-16 大陸商勤浩醫藥(蘇州)有限公司 Amide compound, pharmaceutical composition containing amide compound and use thereof
CN117362286B (en) * 2023-12-08 2024-03-12 清华大学 Compounds with SIRT6 agonistic activity and their uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029318A1 (en) * 1997-12-11 1999-06-17 Biochem Pharma Inc. Antiviral compounds
WO2003037872A1 (en) * 2001-11-01 2003-05-08 Astrazeneca Ab Therapeutic quinoline compounds with 5-ht-antagonistic properties
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
US20060183909A1 (en) * 2001-07-20 2006-08-17 Martine Schmitt Compositions derived from quinoline and quinoxaline, preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773834A2 (en) * 2004-08-03 2007-04-18 Serenex, Inc. 2, 8-disubstituted naphthyridine derivatives
CA2599992A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
CA2717011A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Quinolines as inhibitors of farnesyl pyrophosphate synthase
SG190603A1 (en) * 2008-05-01 2013-06-28 Sirtris Pharmaceuticals Inc Quinolines and related analogs as sirtuin modulators
US8987258B2 (en) * 2008-09-29 2015-03-24 Christopher Oalmann Chromenone analogs as sirtuin modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029318A1 (en) * 1997-12-11 1999-06-17 Biochem Pharma Inc. Antiviral compounds
US20060183909A1 (en) * 2001-07-20 2006-08-17 Martine Schmitt Compositions derived from quinoline and quinoxaline, preparation and use thereof
WO2003037872A1 (en) * 2001-11-01 2003-05-08 Astrazeneca Ab Therapeutic quinoline compounds with 5-ht-antagonistic properties
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010101949A1 *

Also Published As

Publication number Publication date
JP2012519211A (en) 2012-08-23
KR20110128908A (en) 2011-11-30
EP2403833A1 (en) 2012-01-11
BRPI1011477A2 (en) 2016-03-22
CA2754058A1 (en) 2010-09-10
MX2011009213A (en) 2011-12-14
WO2010101949A1 (en) 2010-09-10
CN102414180A (en) 2012-04-11
EA201171098A1 (en) 2012-04-30
IL214943A0 (en) 2011-11-30
AU2010221417A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
IL214943A0 (en) 8-substituted quinolines and related analogs as sirtuin modulators
IL208997A0 (en) Quinolines and related analogs as sirtuin modulators
IL219372A0 (en) Bicyclic pyridines and analogs as sirtuin modulators
IL209567A0 (en) Imidazopyridine and related analogs as sirtuin modulators
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
IL218770A0 (en) Novel modulators
LT2496567T (en) Novel benzopyran kinase modulators
ZA201109535B (en) Game system
IL210206A0 (en) Benzimidazoles and related analogs as sirtuin modulators
EP2350051A4 (en) Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
ZA201107646B (en) Isothiazolo-prrimidinedione derivatives as trpa1 modulators
GB0909909D0 (en) Microcapsules containing microrgnisms
SG10201402723QA (en) Flavonoid hydrogel
IL216176A0 (en) Lxr modulators
PL2496340T3 (en) Silica dispersion
GB0920846D0 (en) Defenin inducing agent
GB0919414D0 (en) Flame effect
AU328865S (en) Nasal plug
GB0918104D0 (en) Helmet
GB0920540D0 (en) Helmet
HU0900183V0 (en) Jewellery for measuring vital parameters
TWM369905U (en) Improved detachable hanging band
GB0902541D0 (en) Methods to identify modulators
AU331514S (en) Jewellery
GB0911268D0 (en) Game system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

A4 Supplementary search report drawn up and despatched

Effective date: 20120731

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/02 20060101ALI20120725BHEP

Ipc: A61K 31/4709 20060101ALI20120725BHEP

Ipc: A61P 9/00 20060101ALI20120725BHEP

Ipc: A61K 31/506 20060101ALI20120725BHEP

Ipc: A61K 31/497 20060101ALI20120725BHEP

Ipc: A61K 31/47 20060101ALI20120725BHEP

Ipc: A61K 31/538 20060101ALI20120725BHEP

Ipc: C07D 487/04 20060101ALI20120725BHEP

Ipc: C07D 417/12 20060101ALI20120725BHEP

Ipc: A61K 31/5377 20060101ALI20120725BHEP

Ipc: A61P 3/00 20060101ALI20120725BHEP

Ipc: A61K 31/501 20060101ALI20120725BHEP

Ipc: C07D 401/14 20060101ALI20120725BHEP

Ipc: C07D 215/48 20060101AFI20120725BHEP

Ipc: A61P 5/50 20060101ALI20120725BHEP

Ipc: A61K 31/4375 20060101ALI20120725BHEP

Ipc: C07D 413/14 20060101ALI20120725BHEP

Ipc: A61K 31/519 20060101ALI20120725BHEP

Ipc: C07D 401/12 20060101ALI20120725BHEP

Ipc: C07D 417/14 20060101ALI20120725BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130228